Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Melichar

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
ESMO Open|July 6, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)G Roviello, F Ciccimarra, F Urabe, et al.
ESMO Open|August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyM Simonelli, E Garralda, F Eskens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
ESMO Open|July 6, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)G Roviello, F Ciccimarra, F Urabe, et al.
ESMO Open|August 20, 2022
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter studyM Simonelli, E Garralda, F Eskens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 11